How to buy Acorda Therapeutics stock - 13 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Acorda Therapeutics stock

Own Acorda Therapeutics stock in just a few minutes.

Acorda Therapeutics, Inc is a biotechnology business based in the US. Acorda Therapeutics shares (ACOR) are listed on the NASDAQ and all prices are listed in US Dollars. Acorda Therapeutics employs 167 staff and has a trailing 12-month revenue of around USD$153 million.

How to buy shares in Acorda Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Acorda Therapeutics. Find the stock by name or ticker symbol: ACOR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Acorda Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Acorda Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Acorda Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Acorda Therapeutics share price

Use our graph to track the performance of ACOR stocks over time.

Acorda Therapeutics shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$2.5344 - USD$8.66
50-day moving average USD$5.6751
200-day moving average USD$5.2112
Wall St. target priceUSD$17.5
PE ratio 1.1057
Dividend yield N/A (0%)
Earnings per share (TTM) USD$6.132

Buy Acorda Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Acorda Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Acorda Therapeutics under- or over-valued?

Valuing Acorda Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Acorda Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Acorda Therapeutics's P/E ratio

Acorda Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Acorda Therapeutics shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Acorda Therapeutics's PEG ratio

Acorda Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.51. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Acorda Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Acorda Therapeutics financials

Revenue TTM USD$153 million
Gross profit TTM USD$96.8 million
Return on assets TTM -7.55%
Return on equity TTM -36.3%
Profit margin -65.11%
Book value $25.127
Market capitalisation USD$44.2 million

TTM: trailing 12 months

Shorting Acorda Therapeutics shares

There are currently 1.1 million Acorda Therapeutics shares held short by investors – that's known as Acorda Therapeutics's "short interest". This figure is 40.4% up from 761,102 last month.

There are a few different ways that this level of interest in shorting Acorda Therapeutics shares can be evaluated.

Acorda Therapeutics's "short interest ratio" (SIR)

Acorda Therapeutics's "short interest ratio" (SIR) is the quantity of Acorda Therapeutics shares currently shorted divided by the average quantity of Acorda Therapeutics shares traded daily (recently around 298551.67597765). Acorda Therapeutics's SIR currently stands at 3.58. In other words for every 100,000 Acorda Therapeutics shares traded daily on the market, roughly 3580 shares are currently held short.

However Acorda Therapeutics's short interest can also be evaluated against the total number of Acorda Therapeutics shares, or, against the total number of tradable Acorda Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acorda Therapeutics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Acorda Therapeutics shares in existence, roughly 110 shares are currently held short) or 0.1252% of the tradable shares (for every 100,000 tradable Acorda Therapeutics shares, roughly 125 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acorda Therapeutics.

Find out more about how you can short Acorda Therapeutics stock.

Acorda Therapeutics share dividends

We're not expecting Acorda Therapeutics to pay a dividend over the next 12 months.

Have Acorda Therapeutics's shares ever split?

Acorda Therapeutics's shares were split on a 1:6 basis on 3 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Acorda Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Acorda Therapeutics shares which in turn could have impacted Acorda Therapeutics's share price.

Acorda Therapeutics share price volatility

Over the last 12 months, Acorda Therapeutics's shares have ranged in value from as little as $2.5344 up to $8.66. A popular way to gauge a stock's volatility is its "beta".

ACOR.US volatility(beta: 0.61)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acorda Therapeutics's is 0.61. This would suggest that Acorda Therapeutics's shares are less volatile than average (for this exchange).

Acorda Therapeutics overview

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site